Search

Your search keyword '"Francisco J Rodríguez-Quiroz"' showing total 3 results
Start Over Author "Francisco J Rodríguez-Quiroz" Topic medicine.medical_specialty
3 results on '"Francisco J Rodríguez-Quiroz"'

1. Presentation and Outcomes of Kawasaki Disease in Latin American Infants Younger Than 6 Months of Age: A Multinational Multicenter Study of the REKAMLATINA Network

Author

Tamara Viviani, Emelia Bainto, Fernanda Cofré, Elizabeth Moreno, Olguita Del Aguila, Dora Estripeaut, Sandra Beltrán, Rolando Ulloa-Gutierrez, Lucila Martínez-Medina, Kathia Luciani, Luis Martín Garrido-García, S Diana Garcia, Martha I Alvarez-Olmos, María Catalina Pírez, Adriana H. Tremoulet, Virgen Gómez, Eduardo López-Medina, Andrea Salgado, Enrique Faugier-Fuentes, Greta Miño-León, Heloisa Helena de Souza Marques, Germán Camacho-Moreno, Patricia Saltigeral-Simental, Benjamin D Rosellini, Lourdes Dueñas, Austin J. Parish, and Francisco J Rodríguez-Quiroz

Subjects
Pediatrics, medicine.medical_specialty, Latin Americans, Clinical Trials and Supportive Activities, 030204 cardiovascular system & hematology, Delayed diagnosis, Paediatrics and Reproductive Medicine, 03 medical and health sciences, 0302 clinical medicine, Clinical Research, 030225 pediatrics, medicine, coronary artery abnormalities, Vulnerable population, delayed diagnosis, Original Research, Coronary artery aneurysm, Pediatric, Other Medical and Health Sciences, Kawasaki disease, infants, business.industry, lcsh:RJ1-570, lcsh:Pediatrics, medicine.disease, Brain Disorders, medicine.anatomical_structure, Latin America, Multicenter study, Pediatrics, Perinatology and Child Health, Presentation (obstetrics), business, Coronary artery abnormalities, Infants, Artery, The REKAMLATINA-2 Study Group Investigators
Abstract

Objective: To characterize the clinical presentation and outcomes of Kawasaki disease (KD) in infants 10 days (50 vs. 7.4%, P = 0.043)]. Conclusion: Our data show that despite treatment in the first 10 days of illness, infants

Published
2020
Full Text
View/download PDF

2. Use of adjunctive therapy in acute Kawasaki disease in Latin America

Author

Brenda Fortuna-Reyna, Emelia V. Bainto, Rolando Ulloa-Gutierrez, Luis M. Garrido-García, Dora Estripeaut, Olguita del Águila, Virgen Gómez, Enrique Faugier-Fuentes, Greta Miño-León, Sandra Beltrán, Fernanda Cofré, Enrique Chacón-Cruz, Patricia Saltigeral-Simental, Lucila Martínez-Medina, Lourdes Dueñas, Kathia Luciani, Francisco J. Rodríguez-Quiroz, German Camacho-Moreno, Tamara Viviani, Martha I. Alvarez-Olmos, Heloisa Helena de Sousa Marques, Eduardo López-Medina, María C. Pirez, and Adriana H. Tremoulet

Subjects
medicine.medical_specialty, Latin Americans, Future studies, adjunctive therapy, Pediatrics, Paediatrics and Reproductive Medicine, Rare Diseases, Internal medicine, medicine, Adjunctive therapy, Original Research, Other Medical and Health Sciences, Kawasaki disease, business.industry, Kawasaki Disease REKAMLATINA Network Study Group, lcsh:RJ1-570, Evaluation of treatments and therapeutic interventions, lcsh:Pediatrics, medicine.disease, Infliximab, Coronary arteries, medicine.anatomical_structure, Latin America, 6.1 Pharmaceuticals, Pediatrics, Perinatology and Child Health, Steroids, business, infliximab, medicine.drug, steroids
Abstract

Objective: To characterize the use of adjunctive therapy in Kawasaki disease (KD) in Latin America. Methods: The study included 1,418 patients from the Latin American KD Network (REKAMLATINA) treated for KD between January 1, 2009, and May 31, 2017. Results: Of these patients, 1,152 received only a single dose of IVIG, and 266 received additional treatment. Age at onset was similar in both groups (median 2 vs. 2.2 years, respectively). The majority of patients were male (58 vs. 63.9%) and were hospitalized with the first 10 days of fever (85.1 vs. 84.2%). The most common adjunctive therapy administered was steroids for IVIG-resistance, followed by additional doses of IVIG. The use of biologics such as infliximab was limited. KD patients who received adjunctive therapy were more likely to have a lower platelet count and albumin level as well as a higher Z score of the coronary arteries. Conclusion: This is the first report of adjunctive therapies for KD across Latin America. IVIG continues to be the initial and resistance treatment, however, steroids are also used and to a lesser extent, biological therapy such as infliximab. Future studies should address the barriers to therapy in children with acute KD throughout Latin America.

Published
2020

3. Abstract O-59

Author

Patricia Saltigeral-Simental, Germán Camacho-Moreno, Kattia Camacho-Badilla, Dora Estripeaut, Rolando Ulloa-Gutierrez, Marco Antonio Yamazaki-Nakashimada, M. Vargas-Gutierrez, Francisco J Rodríguez-Quiroz, Adriana H. Tremoulet, Kathia Luciani, Alejandra Soriano-Fallas, Lourdes Dueñas, R. Rodríguez-Herrera, Andrea Salgado, María L Avila-Aguero, O. del Águila, S. Li-Chan, Luis Martín Garrido-García, and Virgen Gómez

Subjects
Pediatrics, medicine.medical_specialty, Latin Americans, business.industry, Shock (circulatory), Pediatrics, Perinatology and Child Health, medicine, Kawasaki disease, medicine.symptom, Critical Care and Intensive Care Medicine, medicine.disease, business
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results